Description

Moxonidine Film-Coated Tablets (0.2 mg / 0.3 mg / 0.4 mg)

Healthy Inc is a specialized global supplier and exporter of advanced cardiovascular, metabolic, and central nervous system (CNS) antihypertensive therapeutics. We provide ultra-high-purity, kinetically precise Moxonidine Film-Coated Tablets (0.2 mg / 0.3 mg / 0.4 mg), manufactured in WHO–GMP certified, high-precision micro-dosing oral solid dosage facilities. This “Centrally Acting Imidazoline I1 Receptor Agonist” is a highly lucrative, rapidly growing export to cardiology centers, metabolic and diabetic clinics, retail pharmacy networks, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as the globally mandated, high-compliance intervention for resistant hypertension and Metabolic Syndrome-associated high blood pressure.

Product Overview

This highly advanced formulation bypasses the peripheral blood vessels and goes straight to the brainstem. It fundamentally turns down the “volume” of the sympathetic nervous system, eliminating the excess adrenaline that drives severe, treatment-resistant hypertension.

The “Sympathetic Modulator & Metabolic Optimizer” Specialist:

• Mechanism 1 (The I1 Receptor Specificity): Moxonidine selectively binds to Imidazoline Type 1 (I1) receptors located in the rostral ventrolateral medulla (RVLM) of the brainstem. By activating these specific receptors, it severely inhibits the sympathetic outflow from the brain to the cardiovascular system. This causes peripheral blood vessels to relax (vasodilation) and the heart rate to safely decrease, resulting in a profound, sustained drop in blood pressure.
• Mechanism 2 (The Metabolic Syndrome Advantage – CRITICAL): Older antihypertensives (like beta-blockers and thiazide diuretics) notoriously worsen blood sugar control and lipid profiles. Moxonidine does the exact opposite. By turning down chronic sympathetic overactivity, it actively improves insulin sensitivity and reduces insulin resistance. This makes it the absolute gold-standard add-on therapy for the millions of hypertensive patients suffering from Type 2 Diabetes, obesity, and Metabolic Syndrome.
• Mechanism 3 (The “Clonidine Successor” Safety Profile): Older central drugs like Clonidine or Methyldopa heavily bind to Alpha-2 receptors in the brain, which triggers severe dry mouth, extreme sedation, and cognitive fog. Because Moxonidine is highly selective for the I1 receptor (with very low affinity for Alpha-2), it delivers massive blood pressure reduction while allowing the patient to remain alert, awake, and highly compliant with the therapy.

Product Composition & Strength

We supply this product as a Precision-Blended, Micro-Dosed Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the active ingredient.

*Pack Sizes: 10×10 Blisters or 28/30-Tablet Calendar Packs (Optimized specifically for strict chronic cardiology dispensing regimens).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Cardiology Distributors, and Hospital Procurement Boards.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Micro-Dose Content Uniformity Engineering (CRITICAL COMPLIANCE): Manufacturing a drug where the active payload is only 0.2 milligrams is one of the ultimate tests of a pharmaceutical facility. If standard blending is used, some tablets will contain zero Moxonidine, while others will contain a lethal double-dose. Our facilities utilize advanced high-shear wet granulation paired with strict, multi-stage geometric dilution. We routinely achieve Content Uniformity (CU) Relative Standard Deviations (RSD) of less than 3%, guaranteeing absolute clinical safety and precision in every single pill.

Therapeutic Indications (Human Use)

Indicated for the comprehensive, highly targeted management of cardiovascular disease:

• Essential Hypertension: Treatment of mild to moderate high blood pressure, particularly in patients where first-line therapies (ACEi, ARBs, CCBs) are insufficient or poorly tolerated.
• Resistant Hypertension (Add-On Therapy): Highly effective as part of a multi-drug regimen for patients whose blood pressure remains uncontrolled despite maximal standard therapy.
• Metabolic Syndrome / Diabetic Hypertension: The preferred centrally acting agent for patients with concurrent obesity, insulin resistance, or Type 2 Diabetes due to its proven metabolic benefits.

Dosage & Administration

Recommended Dosage (Strictly as per Cardiologist Guidelines):

• Starting Dose: 0.2 mg taken orally once daily in the morning.
• Maintenance Dose: Titrated up to 0.4 mg daily (can be taken as a single morning dose or divided twice daily). The absolute maximum daily dose is 0.6 mg (in divided doses).
• Administration: Can be taken with or without food. Tablets must be swallowed whole with water.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• Heart Failure (Absolute Contraindication): Unlike certain beta-blockers, centrally acting agents like Moxonidine have been shown to increase mortality in patients with severe, symptomatic heart failure (NYHA Class III and IV). It is strictly contraindicated in these patients.
• Severe Renal Impairment: Moxonidine is primarily excreted unchanged by the kidneys. In patients with moderate to severe renal impairment (GFR < 30 mL/min), the drug will build up to toxic levels. Dosages must be drastically reduced, or the drug avoided entirely.
• Abrupt Withdrawal Risk: While the risk of severe “rebound hypertension” is significantly lower than with Clonidine, therapy should still not be stopped abruptly. The dose should be tapered over a period of two weeks to prevent sudden adrenaline spikes.
• Conduction Disorders: Avoid in patients with sick sinus syndrome or 2nd/3rd degree AV block, as it centrally lowers the heart rate.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and Cardiology Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Cardiovascular, Metabolic, and Micro-Dosed Formulations. Whether you are looking for a reliable Government Tender Supplier for hypertension clinics in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely, secure delivery of highly stable, WHO-GMP certified products.